| Literature DB >> 27513941 |
Isabel Oriol1, Laura Lladó2, Marina Vila2, Carme Baliellas2, Fe Tubau3, Núria Sabé1, Joan Fabregat2, Jordi Carratalà1.
Abstract
The role of contaminated preservation fluid in the development of infection after liver transplantation has not been fully elucidated. To assess the incidence and etiology of contaminated preservation fluid and determine its impact on the subsequent development of infection after liver transplantation, we prospectively studied 50 consecutive liver transplants, and cultured the following samples in each instance: preservation fluid (immediately before and at the end of the back-table procedure, and just before implantation), blood, and bile from the donor, and ascitic fluid from the recipient. When any culture was positive, blood cultures were obtained and targeted antimicrobial therapy was started. We found that the incidence of contaminated preservation fluid was 92% (46 of 50 cases of liver transplantation per year), but only 28% (14/50) were contaminated by recognized pathogens. Blood and bile cultures from the donor were positive in 28% and 6% respectively, whereas ascitic fluid was positive in 22%. The most frequently isolated microorganisms were coagulase-negative staphylococci. In nine cases, the microorganisms isolated from the preservation fluid concurred with those grown from the donor blood cultures, and in one case, the isolate matched with the one obtained from bile culture. No liver transplant recipient developed an infection due to the transmission of an organism isolated from the preservation fluid. Our findings indicate that contamination of the preservation fluid is frequent in liver transplantation, and it is mainly caused by saprophytic skin flora. Transmission of infection is low, particularly among those recipients given targeted antimicrobial treatment for organisms isolated in the preservation fluid.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27513941 PMCID: PMC4981323 DOI: 10.1371/journal.pone.0160701
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline liver donor and recipient characteristics, and operation features characteristics.
| CHARACTERISTICS | N = 50 |
|---|---|
| Age, median (IQR) | 63 (51–69) |
| Weight (Kg), median (IQR) | 80 (72–90) |
| Height (m), median (IQR) | 1.7 (1.65–1.8) |
| Male sex, no. (%) | 32 (64) |
| Heart disease, no. (%) | 13 (26) |
| Length of ICU stay, median (IQR) | 2 (1–6) |
| Cold ischemia time (minutes), median (IQR) | 377 (310–480) |
| Length of surgery (minutes), median (IQR) | 385 (344–450) |
| Red blood cell transfusion, no. (%) | 29 (58) |
| Fresh-frozen plasma transfusion, no. (%) | 15 (30) |
| Platelets transfusion, no. (%) | 27 (54) |
| Age, median (IQR) | 57 (52–62) |
| Male sex, no. (%) | 41 (82) |
| HTA pre-LT, no. (%) | 13 (26) |
| DM pre-LT, no. (%) | 9 (18) |
| MELD, median (IQR) | 20 (15–25) |
| Length of ICU stay post-LT (days), median (IQR) | 3 (2–4) |
| Length of hospitalization post-LT (days), median (IQR) | 12 (9–20) |
| Infection during the first month post-LT, no. (%) | 6 (12) |
| Overall case-fatality rate, no. (%) | 1 (2) |
IQR: Interquartile range; ICU: Intensive Care Unit; HTA: arterial hypertension; DM: Diabetes mellitus; LT: liver transplantation; MELD: Model of End-Stage Liver Disease
Microorganisms isolated in the preservation fluid, blood, and bile samples from the donor and in the ascites samples from the recipients.
| Microorganisms | PF-1 | PF -2 | PF -3 | Bile | Blood | Ascites |
|---|---|---|---|---|---|---|
| - | 8 | 32 | 1 | 10 | 7 | |
| - | 1 | 1 | - | - | - | |
| - | - | 5 | - | - | - | |
| - | - | 3 | 1 | - | - | |
| - | - | 1 | - | - | 1 | |
| - | - | 1 | - | - | - | |
| - | - | 2 | - | - | 1 | |
| - | - | 2 | - | - | 1 | |
| - | 1 | 6 | - | 1 | - | |
| - | - | - | 1 | 1 | - | |
| - | - | - | - | 1 | - | |
| - | - | 1 | 1 | - | 1 | |
| - | 1 | 1 | - | - | - | |
| - | - | 1 | - | 1 | - |
CNS, Coagulase-negative staphylococci; MSSA, methicillin-sensitive Staphylococcus aureus; PF, preservation fluid; LT, Liver transplantation.
a PF-1: Preservation fluid collected before the back-table procedure
b PF-2: Preservation fluid at the end of the back-table procedure
c PF-3: Preservation fluid collected just before implantation
d Bile: bile sample from the donor
e Blood: Blood sample from the donor
f Ascites: Ascites sample from the recipient.
Liver recipients with contaminated preservation fluid before implantation: microorganisms involved, susceptibility to antimicrobial prophylaxis, treatment and outcomes.
| Case | Organisms isolated in the PF | AAP | AP | Treatment | Days of treatment | Length of ICU stay (days) | LOS (days) | Infection | Re-transplantation | Death |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Yes | Yes | Ertapenem | 4 | 3 | 9 | No | No | No | |
| 2 | Yes | Yes | Meropenem | 6 | 2 | 26 | Cholangitis and | Ischemic cholangitis | No | |
| 3 | Yes | Yes | Linezolid | 15 | 2 | 12 | No | No | No | |
| 4 | No | No | Ciprofloxacin | 4 | 3 | 8 | No | No | No | |
| 5 | Yes | No | Cefazolin | 6 | 3 | 19 | No | No | No | |
| 6 | No | No | Amoxicillin + Ciprofloxacin | 7 | 3 | 12 | No | No | No | |
| 7 | Yes | No | Teicoplanin/ Daptomycin | 6 | 2 | 12 | No | No | No | |
| 8 | Yes | No | Aztreonam + Teicoplanin | 5 | 4 | 12 | No | No | No | |
| 9 | Yes | No | Ertapenem | 10 | 8 | 34 | No | No | No | |
| 10 | Yes | No | Linezolid | 9 | 10 | 23 | No | No | No | |
| 11 | Yes | No | Ceftriaxone | 4 | 2 | 7 | No | No | No | |
| 12 | Yes | No | Daptomycin | 5 | 2 | 8 | No | No | No | |
| 13 | Yes | Yes | Ceftriaxone | 7 | 10 | 37 | No | No | No | |
| 14 | No | No | Anidulafungin | 7 | 2 | 10 | No | No | No |
Abbreviations: AAP, adequate antibiotic prophylaxis; AP, antifungal prophylaxis; CNS, Coagulase-negative staphylococci; ICU, Intensive Care Unit; LOS, Length of hospitalization post-LT; N, no; PF, preservation fluid; Y, yes
1 Infection during the first month post-LT
Comparative analysis by the culture result from the preservation fluid just before implantation.
| Characteristics | Univariable analysis | ||
|---|---|---|---|
| Pathogens N = 14 | Negative or SSF N = 36 | p-value | |
| Male sex | 8 (57.1%) | 24 (66.7%) | 0.529 |
| Age (years) | 63.0 (53.8–73.3) | 63.0 (51.0–69.0) | 0.455 |
| Diabetes mellitus | 3 (23.1%) | 10 (27.8%) | 1 |
| Heart disease | 3 (21.4%) | 10 (27.8%) | 1 |
| Length of ICU stay (Days) | 1.0 (1.0–4.3) | 3.0 (2.0–6.0) | 0.033 |
| Cold ischemia time (minutes) | 411 (310–458) | 360 (290–480) | 0.582 |
| Length of surgery (minutes) | 360 (308–458) | 390 (350–450) | 0.380 |
| Length of ICU stay post-LT (days) | 3.0 (2.0–5.0) | 2.0 (2.0–4.0) | 0.582 |
| LOS post-LT (days) | 12.0 (8.8–23.8) | 11.0 (8.0–19.0) | 0.871 |
| Acute graft rejection | 0 | 2 (5.6%) | 1 |
| Infection during the first month of LT | 1(7.1%) | 5 (13.9%) | 0.663 |
ICU: Intensive Care Unit; MELD: Model of End-Stage Liver Disease; LOS: Length of stay; LT: liver transplantation; SSF, superficial saprophytic flora.